Clinical development failure
Lead programs may not demonstrate sufficient safety or efficacy in trials.
- Scope
- ORIC-944, ORIC-114, ORIC-533
- Materiality
- high
Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance. Its pipeline centers on oncology programs in hormone-dependent cancers, precision oncology, and key tumor dependencies, with development activities run from its South San Francisco headquarters.
14.13
14.13
| % | |
|---|---|
| Clinical-stage oncology programs | 100% Investigational drug candidates in human clinical trials for cancer. |
| Preclinical discovery pipeline | 0% Earlier-stage internal and in-licensed programs aimed at resistance mechanisms. |
ORIC does not sell commercial products today; its direct counterparties are clinical trial sites, research...
- Clinical trial collaboratorsprimary
Hospitals, investigators, and research networks that enroll patients and run ORIC-sponsored studies.
- Pharmaceutical partnersprimary
Companies such as Johnson & Johnson and Bayer that supply combination agents and support studies.
- Licensors and biotech counterpartiessecondary
Owners of external programs that ORIC in-licenses to expand its pipeline.
- Future oncology patientsemerging
Patients with resistant cancers who would use ORIC therapies if approved.
ORIC is headquartered in South San Francisco, California and operates as a U.S.-based development company...
- •Headquartered in South San Francisco, California
- •Clinical development and regulatory work are centered in the United States
- •Trials may enroll patients across multiple countries and sites
- •Future commercialization would depend on oncology markets in North America and abroad
ORIC’s strategy is to concentrate resources on a small number of differentiated oncology assets, especially ORIC-944...
01
Advance ORIC-944 through late-stage developmentshort-term
This is a lead asset in resistant prostate cancer and a core value driver.
02
Develop ORIC-114 as a precision oncology programmedium-term
It broadens the pipeline beyond hormone-dependent cancers and targets resistant mutations.
03
Use business development to expand the pipelinemedium-term
External innovation can add assets without relying only on internal discovery.
ORIC is a clinical-stage company with no commercial revenue, so its value depends heavily on successful clinical...
Capital dependence
The company has no revenue and must fund long development timelines.
- Scope
- Corporate-wide
- Materiality
- high
Third-party reliance
Trials, manufacturing, and combination studies depend on external partners and suppliers.
- Scope
- CROs, CMOs, licensors, pharma collaborators
- Materiality
- high
Competitive pressure
Large oncology companies can move faster, fund more studies, and reach patients sooner.
- Scope
- Prostate cancer and precision oncology
- Materiality
- high
Research and development expense recognition
Affects operating loss and comparability across periods
Stock-based compensation
Affects operating expenses and net loss
Clinical trial accruals
Affects R&D expense timing
Investment valuation and maturities
Affects balance sheet and other income
: 29.4.2026